申请人:Fujisawa Pharmaceutical Co., Ltd.
公开号:US04621084A1
公开(公告)日:1986-11-04
New imidazo-heterocyclic compounds of the formula: ##STR1## wherein R.sup.1 is hydrogen, lower alkyl or halogen, R.sup.2 is hydrogen, lower alkyl, halogen, aminomethyl optionally substituted with lower alkyl, or piperazin-1-yl-methyl optionally substituted with lower alkyl, R.sup.3 is a partially suturated heterocyclic group selected from benzothiazolinyl, benzoxazolinyl, benzimidazolinyl, 3,4-dihydro-2H-1,4-benzothiazinyl, 3,4-dihydro-2H-1,4-benzoxazinyl and 1,2,3,4-tetrahydroquinoxalinyl, which is substituted with oxo, thioxo, imino or lower alkylimino, and which may be substituted with lower alkyl optionally substituted with lower alkanoyloxy, lower alkoxycarbonyl, pyridyl or lower alkylamino; or an unsaturated heterocyclic group selected from benzoxazolyl and benzimidazolyl, which may be substituted with lower alkyl or pyridyl(lower)alkylthio, and Y is .dbd.N-- or a group of the formula: ##STR2## in which R.sup.4 is hydrogen, hydroxy, lower alkyl, lower alkoxy or ar(lower)alkoxy, and pharmaceutically acceptable salts thereof, and processes for preparation thereof and pharmaceutical composition comprising the same. These derivatives and pharmaceutically acceptable salts thereof are useful as cardiotonic agents and untiulcer agents.
新的咪唑杂环衍生物,其化学式为:##STR1## 其中R.sup.1为氢、低碳基或卤素,R.sup.2为氢、低碳基、卤素、氨甲基(可选用低碳基取代)或哌嗪-1-基甲基(可选用低碳基取代),R.sup.3为部分饱和杂环基,选自苯并噻唑啉基、苯并噁唑啉基、苯并咪唑啉基、3,4-二氢-2H-1,4-苯并噻嗪基、3,4-二氢-2H-1,4-苯并噁嗪基和1,2,3,4-四氢喹喔啉基,其被氧、硫氧、亚氨基或低碳基亚氨基取代,且可用低碳基(可选用低碳酰氧基、低碳氧羰基、吡啶基或低碳基氨基取代)取代;或者为不饱和杂环基,选自苯并噁唑基和苯并咪唑基,其可用低碳基或吡啶基(低)烷硫基取代,Y为.dbd.N-或化学式:##STR2## 在其中R.sup.4为氢、羟基、低碳基、低碳氧基或芳基(低)烷氧基,以及其药学上可接受的盐,以及制备方法和包含其的制药组合物。这些衍生物和药学上可接受的盐作为心力衰竭药物和抗溃疡药物有用。